Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
SOUTH SAN FRANCISCO, Calif., July 5, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medication oncology firm dedicated to the invention and...
Endocrinology–Nephrology Analysis Axis, Centre de recherche du CHU de Québec, Université Laval, Québec Metropolis, Québec, CanadaLucas Galey & Étienne Audet-WalshDivision of Molecular Medication, College of...